Company news

Foghorn Therapeutics Inc. news in 2025

Foghorn Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

November 5, 2025

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

November 3, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

October 30, 2025

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

October 16, 2025

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

August 5, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

May 22, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 14, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

May 5, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

May 1, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

April 28, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

April 15, 2025

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

March 25, 2025

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

March 6, 2025

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

February 25, 2025

Decks in 2025